ALVO vs GILD: fair value comparison
Alvotech and Gilead Sciences, Inc. · Updated 2026-10-19
ALVO's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, ALVO currently ranks higher by quality score.
| ALVO | GILD | |
|---|---|---|
| Verdict | Awaiting full valuation | Overvalued |
| Last price | $5.00 | $151.17 |
| 12-month range | $3.00–$8.40 | $117.88–$157.37 |
| Rank by discount to fair value | — | #85 of 108 Healthcare |
| Rank by quality score | #117 of 301 Healthcare | #118 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: ALVO fair value analysis · GILD fair value analysis